Mycovia Pharmaceuticals Email Format

Pharmaceutical ManufacturingNorth Carolina, United States2-10 Employees

Mycovia Pharmaceuticals, Inc. was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. 

Mycovia Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies. VIVJOA® (oteseconazole) capsules, the first FDA-approved product for Mycovia, is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to become the first FDA-approved therapy for RVVC. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Pharmaceuticals Co., Ltd., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens.

Sign up for free to view info

Company overview Employee directory